AIM ImmunoTech Inc. (AIM) stock

AIMNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 3/30

$0.14−0.01 (-3.36%)

Close on Nov 13, 2026Market cap $4.37MP/E –Yield –

AIM ImmunoTech price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

AIM ImmunoTech's price to book ratio was 0.6× on Nov 11, 2026, against 3.2× a year earlier. Over the last 5 years it ranged from 0.3× to 4.6×, with a median of 1.0×.

Price to Book Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	0.6×	−3.5
2025	Jan 31, 2025	4.1×	+0.1
2024	Dec 31, 2024	4.0×	+3.0
2023	Dec 29, 2023	0.9×	+0.6
2022	Dec 30, 2022	0.3×	−0.4
2021	Dec 31, 2021	0.7×	−0.5
2020	Dec 31, 2020	1.2×	+0.9
2019	Dec 31, 2019	0.2×	−1.1
2018	Dec 31, 2018	1.3×	+0.3
2017	Dec 29, 2017	1.1×	+0.1
2016	Dec 30, 2016	1.0×	−1.1
2015	Apr 30, 2015	2.1×	+0.2
2014	Apr 30, 2014	1.9×	+1.1
2013	Apr 30, 2013	0.8×	–

Where these numbers come from

Parsed from the XBRL in AIM ImmunoTech's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-100 reverse split on Jun 12, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AIM.

Compare: AIM vs INMB · AIM vs ABPO · AIM vs ARTV · AIM vs ATYR · AIM vs HIND

Company	Revenue	Growth
HIND	$153.10K	-55.6%
AIM	$91.00K	-18.8%
INMB	–	–
ABPO	–	–
ARTV	–	–
ATYR	–	–

Company

Exchange: NYSE
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Held by institutions: 3.8%
Auditor: BDO USA, P.C.
SEC CIK: 946644

Advertisement
300 × 250

See a number that looks wrong?

AIM ImmunoTech price to book ratio

Price to Book Ratio at the end of each year

More AIM ImmunoTech figures